A5083460869- Autoimmune and Inflammatory Disorders Research
- Inflammatory Myopathies and Dermatomyositis
- Systemic Lupus Erythematosus Research
- Innovations in Medical Education
- Childhood Cancer Survivors' Quality of Life
- Adolescent and Pediatric Healthcare
- Musculoskeletal Disorders and Rehabilitation
- Vasculitis and related conditions
- Eosinophilic Disorders and Syndromes
- Pediatric Pain Management Techniques
- Bipolar Disorder and Treatment
- Rheumatoid Arthritis Research and Therapies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Immunodeficiency and Autoimmune Disorders
- Genetic factors in colorectal cancer
- Immune Cell Function and Interaction
- Renal Diseases and Glomerulopathies
- Skin Diseases and Diabetes
- Muscle and Compartmental Disorders
- Urticaria and Related Conditions
Boston Children's Hospital
2024-2025
Harvard University
2025
Children's Hospital Colorado
2023-2024
University of Colorado Denver
2023-2024
Boston Children's Museum
2024
Children's Hospital at Montefiore
2021-2023
Objective Disordered T peripheral helper (Tph)‐B cell interactions have been implicated in several forms of inflammatory arthritis, including oligoarticular juvenile idiopathic arthritis (oligo JIA). We sought to evaluate the Tph‐B axis oligo JIA through an analysis intra‐articular B cells. Methods cells from blood and synovial fluid (SF) 44 children with were compared those tonsils controls. Flow cytometry, receptor (BCR) repertoire analysis, autoantibody profiling used characterize Results...
Abstract Objective To establish the minimal change on a pain visual analog scale (VAS) associated with in self‐reported quality of life pediatric rheumatology patients. Methods Subjects were cohort 533 patients Toronto. Pain and perceived measured at 2 consecutive visits to clinic. Results Among who rated second visit as “a little better” “much better,” mean score 10‐cm VAS was reduced by 0.82 1.45 cm, respectively. For those whose changed worse” worse,” scores increased 1.90 3.69 cm....
Abstract Background Despite new and better treatments for juvenile dermatomyositis (JDM), not all patients with moderate severity disease respond adequately to first-line therapy. Those refractory remain at higher risk glucocorticoid-related complications. Biologic disease-modifying antirheumatic drugs (DMARDs) have become part of the arsenal JDM. However, prospective comparative studies commonly used biologics are lacking. Methods The Childhood Arthritis Rheumatology Research Alliance...
Abstract Background Juvenile idiopathic inflammatory myopathies (JIIMs) is a group of autoimmune disorders, including juvenile dermatomyositis (JDM), polymyositis (JPM) and overlap myositis, that are characterized by proximal muscle weakness, elevated levels serum enzymes, pathognomonic skin findings. While the exact etiology JIIMs unclear, presence myositis specific autoantibodies (MSAs) have been associated with certain clinical phenotypes, organ involvement disease prognosis. To date,...
Musculoskeletal ultrasound (MSUS) is widely used in adult rheumatology practice for diagnosis of arthritis and procedural guidance; however, it not yet common pediatric rheumatology. MSUS advantageous to the population because lacks radiation eliminates need sedation. This study aims assess interest in, access to, barriers training fellowship programs North America.
Objective The objective was to develop consensus treatment plans (CTPs) for patients with refractory moderately severe juvenile dermatomyositis (JDM) treated biologic disease‐modifying antirheumatic drugs (bDMARDs). Methods Biologics Workgroup of the Childhood Arthritis and Rheumatology Research Alliance JDM Committee used case‐based surveys, framework, nominal group technique produce bDMARD CTPs JDM. Results Four were proposed: tumor necrosis factor α (TNFα) inhibitor (adalimumab or...
Children with juvenile dermatomyositis (JDM) and antibodies to antimelanoma differentiation-associated gene 5 (anti-MDA5) are at increased risk of severe disease complications, including interstitial lung (ILD). Data regarding treatment complications in this patient population limited. In study, we examined the course children JDM anti-MDA5 before after rituximab (RTX).Patients aged 2-21 years seen Children's Hospital Montefiore between July 2012 August 2021, a diagnosis JDM, positive...
Growing evidence suggests that infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may trigger idiopathic inflammatory myopathies (IIM). Few studies have described individual juvenile IIM (JIIM) cases following SARS-CoV-2 infection, and none explored its potential effects on JIIM clinical presentation. We aim to investigate the impact of in patients diagnosed before after onset Coronavirus Disease 2019 (COVID-19) pandemic.Patients age 19 at The Children's Hospital...